The spectrum of human diseases is changing with a dramatic increase in the prevalence of chronic diseases (CDs). It is estimated that 88% of deaths worldwide are caused by CDs. China is launching a campaign to combat the four major CDs: cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, and diabetes mellitus. Lack of health knowledge among ordinary people and the increasingly high prevalence of lifestyle risk factors such as smoking, alcohol consumption, physical inactivity, and unhealthy diet contribute significantly to today’s high prevalence of CDs, imposing an enormous economic burden on the healthcare system, society, and individuals.
Inflammation is an evolutionarily conserved self-healing process involving immune and non-immune cells to eliminate pathogens and promote tissue repair and recovery. Environmental, genetic, and lifestyle factors can dysregulate a normal inflammatory response, leading to chronic inflammation and eventually CDs. Despite the recognition of a close link between chronic inflammation and CDs, the mechanisms of CD pathogenesis remain to be fully understood. Although new knowledge about CDs has emerged in the past decade, its impact on clinical practice is limited.
Herbal medicine using botanical products with a definite chemical composition has been applied to prevent, treat and reverse CDs and shows promising results, representing an alternative, effective therapeutic strategy for CDs. Furthermore, it is known that certain herbal medications regulate inflammatory reactions and immune responses. However, the exact mechanisms of action of herbal medications in the treatment of CDs are not completely resolved. Therefore, research in anti-inflammatory immunopharmacology plays a key role in the battle against CDs, which leads to the discovery and development of new medicines and helps us better understand the disease mechanisms. Therefore, our goal is to encourage scientists and clinicians to share their studies relevant to anti-inflammatory immunopharmacology in preventing and treating major CDs.
We welcome submissions in the form of original research article, review (including systematic review and meta-analysis), short communication, opinion, database, meeting summary, book review, letter to the editor, etc. Scope of this Research Topic includes, but is not limited to the following:
• The discovery and development of drugs for the prevention and treatment of major CDs focusing on anti-inflammatory and immune pharmacology
• Elucidation of mechanisms of action of drugs
• Investigation of inflammatory immune mechanisms of major CDs
• Pharmacological management of CDs (preclinical and clinical).
Studies using compounds with a definite chemical composition will be accepted and considered for publication. Those with crude extracts or mixtures will be rejected without further review.
The spectrum of human diseases is changing with a dramatic increase in the prevalence of chronic diseases (CDs). It is estimated that 88% of deaths worldwide are caused by CDs. China is launching a campaign to combat the four major CDs: cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, and diabetes mellitus. Lack of health knowledge among ordinary people and the increasingly high prevalence of lifestyle risk factors such as smoking, alcohol consumption, physical inactivity, and unhealthy diet contribute significantly to today’s high prevalence of CDs, imposing an enormous economic burden on the healthcare system, society, and individuals.
Inflammation is an evolutionarily conserved self-healing process involving immune and non-immune cells to eliminate pathogens and promote tissue repair and recovery. Environmental, genetic, and lifestyle factors can dysregulate a normal inflammatory response, leading to chronic inflammation and eventually CDs. Despite the recognition of a close link between chronic inflammation and CDs, the mechanisms of CD pathogenesis remain to be fully understood. Although new knowledge about CDs has emerged in the past decade, its impact on clinical practice is limited.
Herbal medicine using botanical products with a definite chemical composition has been applied to prevent, treat and reverse CDs and shows promising results, representing an alternative, effective therapeutic strategy for CDs. Furthermore, it is known that certain herbal medications regulate inflammatory reactions and immune responses. However, the exact mechanisms of action of herbal medications in the treatment of CDs are not completely resolved. Therefore, research in anti-inflammatory immunopharmacology plays a key role in the battle against CDs, which leads to the discovery and development of new medicines and helps us better understand the disease mechanisms. Therefore, our goal is to encourage scientists and clinicians to share their studies relevant to anti-inflammatory immunopharmacology in preventing and treating major CDs.
We welcome submissions in the form of original research article, review (including systematic review and meta-analysis), short communication, opinion, database, meeting summary, book review, letter to the editor, etc. Scope of this Research Topic includes, but is not limited to the following:
• The discovery and development of drugs for the prevention and treatment of major CDs focusing on anti-inflammatory and immune pharmacology
• Elucidation of mechanisms of action of drugs
• Investigation of inflammatory immune mechanisms of major CDs
• Pharmacological management of CDs (preclinical and clinical).
Studies using compounds with a definite chemical composition will be accepted and considered for publication. Those with crude extracts or mixtures will be rejected without further review.
